Pittenger & Anderson Inc. Acquires Shares of 2,813 DexCom, Inc. (NASDAQ:DXCM)

Pittenger & Anderson Inc. bought a new stake in DexCom, Inc. (NASDAQ:DXCM) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 2,813 shares of the medical device company’s stock, valued at approximately $349,000.

Several other large investors have also modified their holdings of the stock. Valley National Advisers Inc. grew its position in shares of DexCom by 73.0% during the fourth quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock worth $30,000 after buying an additional 103 shares in the last quarter. MV Capital Management Inc. raised its stake in shares of DexCom by 99.3% during the fourth quarter. MV Capital Management Inc. now owns 277 shares of the medical device company’s stock valued at $34,000 after purchasing an additional 138 shares in the last quarter. Washington Trust Advisors Inc. raised its stake in shares of DexCom by 120.6% during the fourth quarter. Washington Trust Advisors Inc. now owns 353 shares of the medical device company’s stock valued at $44,000 after purchasing an additional 193 shares in the last quarter. NBC Securities Inc. acquired a new position in DexCom during the third quarter worth about $47,000. Finally, Thompson Siegel & Walmsley LLC acquired a new position in DexCom during the third quarter worth about $48,000. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at DexCom

In other news, EVP Sadie Stern sold 20,321 shares of DexCom stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $133.61, for a total value of $2,715,088.81. Following the transaction, the executive vice president now owns 80,441 shares in the company, valued at $10,747,722.01. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In related news, EVP Michael Jon Brown sold 2,624 shares of the business’s stock in a transaction that occurred on Thursday, March 28th. The shares were sold at an average price of $140.04, for a total value of $367,464.96. Following the completion of the transaction, the executive vice president now directly owns 68,682 shares in the company, valued at approximately $9,618,227.28. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Sadie Stern sold 20,321 shares of the firm’s stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $133.61, for a total value of $2,715,088.81. Following the completion of the transaction, the executive vice president now owns 80,441 shares in the company, valued at $10,747,722.01. The disclosure for this sale can be found here. Insiders have sold 189,375 shares of company stock worth $25,530,859 over the last 90 days. Corporate insiders own 0.41% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on DXCM. StockNews.com downgraded DexCom from a “buy” rating to a “hold” rating in a report on Tuesday. Raymond James upped their target price on DexCom from $147.00 to $151.00 and gave the company a “strong-buy” rating in a research note on Tuesday, January 23rd. UBS Group increased their price objective on DexCom from $153.00 to $163.00 and gave the stock a “buy” rating in a research note on Wednesday, April 10th. Royal Bank of Canada initiated coverage on DexCom in a report on Tuesday, March 12th. They set an “outperform” rating and a $165.00 target price on the stock. Finally, Citigroup raised their price target on DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a report on Wednesday, April 3rd. Three equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $141.40.

DexCom Stock Up 0.1 %

NASDAQ:DXCM traded up $0.14 on Thursday, hitting $138.01. The stock had a trading volume of 4,107,206 shares, compared to its average volume of 2,976,416. The company has a market cap of $54.66 billion, a PE ratio of 105.25, a P/E/G ratio of 2.30 and a beta of 1.20. DexCom, Inc. has a 52 week low of $74.75 and a 52 week high of $142.00. The business’s fifty day moving average is $130.58 and its 200 day moving average is $117.88. The company has a quick ratio of 2.48, a current ratio of 2.84 and a debt-to-equity ratio of 1.18.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, February 8th. The medical device company reported $0.50 EPS for the quarter, topping analysts’ consensus estimates of $0.43 by $0.07. The firm had revenue of $1.03 billion during the quarter, compared to analyst estimates of $1.02 billion. DexCom had a return on equity of 28.31% and a net margin of 14.95%. The business’s revenue for the quarter was up 26.9% on a year-over-year basis. During the same period last year, the company earned $0.34 earnings per share. On average, equities research analysts expect that DexCom, Inc. will post 1.76 EPS for the current fiscal year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.